Trial Profile
Special Drug Use Investigation of Nexavar (Unresectable or Advanced Renal Cell Carcinoma).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Mar 2019
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Bayer
- 16 Feb 2019 Results assessing the real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease, presented at the 2019 Genitourinary Cancers Symposium
- 12 Jun 2018 Results published in the British Journal of Cancer
- 12 Sep 2017 Results assessing the safety and efficacy of sorafenib in advanced renal cell carcinoma patients with renal insufficiency (n=1226), presented at the 42nd European Society for Medical Oncology Congress.